Pharma Exports Register Growth Of 10.3% In May, Imports Decline 14.5%


New Delhi : Exports of pharmaceuticals from the country has continued to register a growth of around 10 per cent during the month of May, 2022, in line with the exports trend reported in the first month of the fiscal 2022-23, according to the quick estimates for selected major commodities for the month released by the ministry of commerce and industry.

Exports of drugs and pharmaceuticals during May crossed $2.07 billion as compared to $1.87 billion during the same month of last year. The growth registered was 10.28 per cent, said the Ministry.

Exports for the two months including April and May, 2022, have witnessed a growth to $4.13 billion, as compared to $3.77 billion reported during the corresponding two months of last fiscal year.

Imports of medicinal and pharmaceutical products, on the other hand, registered a decline of 14.52 per cent in May, to $695.42 million as compared to $813.53 million during the same period of previous year. For the two months of April and May, 2022, the imports declined 6.05 per cent, at $1.40 billion as compared to $1.49 billion in the same two months of the previous fiscal year.

It may be noted that the imports during April, 2022, was $710 million, which was a growth of 4.35 per cent from $681 million during the same period of previous year.

Exports, however, continued the growth momentum of April, as April witnessed a growth of 9.49 per cent at $2.07 billion as compared to $1.9 billion during the same month of last year.

When compared to the exports during March also, the April exports showed a significant growth.

The exports of drugs and pharmaceuticals during the fiscal year 2021-22 witnessed a growth of 0.66 per cent at $24.6 billion as compared to $24.44 billion during the previous fiscal year, according to the preliminary estimates of the Department of Commerce.

The Government was targeting an export of $29 billion during the fiscal, but the market conditions were not in tune to support that growth, said experts.

The Central government, earlier this year, said that the Indian pharma exports witnessed a growth of 103 per cent since 2013-14, from Rs. 90, 415 crore in 2013-14 to Rs. 1,83,422 crore in 2021-22. The exports achieved in 2021-22 is the pharma sector’s best export performance ever, it claimed.

It said that the pharma exports in 2021-22 sustained a positive growth despite the global trade disruptions and drop in demand for Covid related medicines. The trade balance continues to be in India’s favour, with a surplus of $15.18 billion, it said.

Indian pharma companies, enabled by their price competitiveness and good quality, have made global mark, with 60 percent of the world’s vaccines and 20% of generic medicines coming from India.

The share of pharmaceuticals and drugs in India’s global exports is 5.92%. Formulations and biologicals continue to account for a major share of 73.31% in total exports, followed by bulk drugs and drug intermediates with exports of $4.44 billion. India’s top 5 pharma export destinations are US, UK, South Africa, Russia and Nigeria.

It is also noteworthy that around 55 per cent of its pharma exports cater to highly regulated markets. Indian pharma companies have a substantial share in the prescription market in the US and EU. The largest number of US Food and Drug Administration approved plants outside the US is in India.

In the year 2020-21, Indian drugs and pharmaceuticals had registered a sharp growth amid the Covid-19 despair, achieving an export of $24.4 billion with a YoY growth of 18%.


Please enter your comment!
Please enter your name here